BullMarket.com Updates Outlooks on Solar Stocks
|
| Posted
:
Tue, 03 Nov 2009 15:07:46 GMT |
| Author
:
Indie Research Advisors, LLC |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
PRINCETON, N.J., Nov. 3 NJ-BullMarket-solar
PRINCETON, N.J., Nov. 3 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with updated coverage on solar stocks, including First Solar (Nasdaq: FSLR), Suntech Power (NYSE: STP), and SunPower (Nasdaq: SPWRA, SPWRB).
All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which outperformed the S&P 500 by 15% in 2008 and was up over 33% year to date at the end of September.
Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/pr/?refer=BMR635P
In its daily report, BullMarket.com wrote: "First Solar's shares got clobbered for what appears to be a decent quarter, but the real pressure comes from worries about what lies ahead. Industry executives, we note, are actually pretty optimistic about next year and the year after."
BullMarket.com looked at the following topics, among others:
-- Why did SunPower's share price plunge despite the company reporting solid third quarter results?
-- Which stock is Bull Market's favorite in the solar space and why?
-- What problems is First Solar facing and should investors be concerned?
-- How will the falling price of silicon impact solar companies in coming years?
About BullMarket.com:
Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.
NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Marcie Martin, Bull Market Report, +1-888-278-5515
SOURCE Indie Research Advisors, LLC
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
Teledata ICT of Ghana Selects VocalTec for Class-5 VoIP HERZLIA, Israel -
VocalTec Communications Ltd. (NASDAQ:VOCL) (the “Company” or
“VocalTec”), a global provider of carrier-class multimedia and
voice-over-IP solutions for communication service providers, today
announced that Teledata ICT, a Ghana-based licensed ISP, se
Ipsen Initiates an Advanced Endometrial Cancer Program with BN83495, its First-in-Class Steroid Sulfatase (STS) Inhibitor First Patient Dosed in Phase II PARIS -
Regulatory News:
Ipsen (Paris:IPN) today announced the initiation of an international,
multi-center, controlled, randomized Phase II clinical trial to evaluate
the safety and efficacy of BN83495, its investigational first-in-class
steroid sulfa
Nortel Selects Ericsson and Kapsch as Successful Bidders for GSM/GSM-R Business TORONTO, ONTARIO -- 11/25/09 --
Nortel(1) Networks Corporation (OTCBB: NRTLQ) announced that it, its principal operating subsidiary Nortel Networks Limited (NNL), and certain of its other subsidiaries, including Nortel Networks Inc., Nortel Network..
Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs WILMINGTON, Del. -
Incyte Corporation (NASDAQ: INCY) announced today that it has entered
into a collaboration and license agreement with Novartis for two of its
investigational hematology-oncology therapies: INCB18424, an oral
JAK1/JAK2 inhibitor that is in Phase III development for myelofib
New Book is a Guide to Killer Online Press Releases for PR Pros and Small Businesses
The optimized press release (or SEO press release) is revitalizing the traditional press release. Combined with social media, news can be a powerful online marketing tool. A new book tells PR professionals, entrepreneurs and small business the secrets to killer online press releases./I/P
...
gategroup Signs Multiple Contracts With Delta Air Lines
ZURICH, Nov. 25 /PRNewswire/ -- gategroup announced the completion of major contract renewals with Delta Air Lines and its Northwest Airlines subsidiary as part of the carriers' continuing progress to integrate supply contracts.
The multi-year deal, encompassing more tha...
BLADE Network Technologies and Emulex Deliver Essential Networking Components for IBM BladeCenter Virtual Fabric PARIS -
Emulex
Corporation (NYSE:ELX) and BLADE Network Technologies, Inc. (
|
|
|
|
|
|
|
|
|